Benzgalantamine

In today's world, Benzgalantamine plays a fundamental role in society. Its importance covers multiple aspects, from its impact on the economy to its influence on popular culture. Throughout history, Benzgalantamine has been the subject of study and debate, generating countless opinions and theories that seek to understand its true meaning. In this article, we will delve into the fascinating world of Benzgalantamine, exploring its different facets and its relevance in everyday life. We will learn about its impact on people's lives, as well as its role in shaping the current world. Join us on this journey to discover everything Benzgalantamine has to offer.

Benzgalantamine
Clinical data
Trade namesZunveyl
Other namesALPHA-1062
AHFS/Drugs.comZunveyl
License data
Routes of
administration		By mouth
Drug classCholinesterase inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H25NO4
Molar mass391.467 g·mol−1
3D model (JSmol)
  • COc1ccc2c3c1O1C(OC(=O)c4ccccc4)C=C31CCN(C)C2
  • InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
  • Key:JKVNJTYHRABHIY-WXVUKLJWSA-N

Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type.[1] It is a cholinesterase inhibitor.[1] Benzgalantamine is a prodrug of galantamine.[1]

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]

Benzgalantamine was approved for medical use in the United States in July 2024.[1][2][3]

Medical uses

Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.[1][2]

Side effects

The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]

Society and culture

Benzgalantamine was approved for medical use in the United States in July 2024.[1][2]

Names

Benzgalantamine is the international nonproprietary name.[4]

References

  1. ^ a b c d e f g h i "Zunveyl- benzgalantamine tablet, delayed release". DailyMed. 8 August 2024. Retrieved 15 August 2024.
  2. ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218549Orig1s000ltr.pdf
  3. ^ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024 – via Business Wire.
  4. ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.